Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study

Kalzenschlager, R.; Evans, A.; Manson, A.; Patsalos, P. N.; Ratnaral, N.; Walt, H.; Timmermann, L.; Van Der Giessen, R.; Lees, A. J.
December 2004
Journal of Neurology, Neurosurgery & Psychiatry;Dec2004, Vol. 75 Issue 12, p1672
Academic Journal
Background: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (L-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard L-dopa/carbidopa (LD/CD). Methods: Eight Parkinson's disease patients with a short duration L-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/ 50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. L-Dopa pharmacokinetics were determined, and Unified Parkinson's Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales. Results: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 mm; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations. Mean on time was 21.9% (37 mm) longer with 30 g mucuna than with LD/CD (p=0.021); peak L-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred. Conclusions: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of L-dopa might possess advantages over conventional L-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.


Related Articles

  • 1997 Royal College mealist in medicine.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS112 

    Presents an abstract of the research manuscript `Experimental investigation of levodopa-induced dyskinesia in a primate model of Parkinsonism,' by P.J. Blanchet.

  • Actions of the D[sub 1] agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Pearce, R. K. B.; Jackson, M.; Britton, D. R.; Shiosaki, K.; Jenner, P.; Marsden, C. D. // Psychopharmacology;1999, Vol. 142 Issue 1, p51 

    Abstract Common marmosets show parkinsonian motor deficits following 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration and develop dyskinesias during chronic L-dopa exposure. The D[sub l] agonists A-77636 [(1R, 3S) 3-(l'-adamantyl)-l-aminomethyl-3, 4-dihydro-5,...

  • Resolution of dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Caradoc-Davies, T.H. // British Medical Journal (Clinical Research Edition);7/5/1986, Vol. 293 Issue 6538, p38 

    Investigates the dyskinesia and the 'on-off' phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment. Difficulty of diagnosing thyrotoxins; Complications of treatment with compounds containing levodopa; Response of patients to the thyrotrophin releasing hormone...

  • Characterization of poly phenol oxidase in two in vitro regenerated cultivars of Mucuna: Mucuna pruriens L. and Mucuna prurita H. Sathyanarayana, Raghavendra; Kumar, Vadlapudi; Ramesh, Chapeyil Kumaran; Parmesha, Mahadevappa; Khan, Mahaboob Habeebulla Moinuddin // Turkish Journal of Biology;2011, Vol. 25 Issue 5, p575 

    Polyphenol oxidases (PPOs EC were isolated from Mucuna pruriens and Mucuna prurita and confirmed as tyrosinases involved in L-DOPA production. PPOs were extracted by using a 0.05 M phosphate buffer, pH 7.0. The purified enzyme was resolved into a single band by PAGE, the enzyme was...

  • Questions and answers about Parkinson's disease.  // Patient Care;Sep2006, Vol. 40 Issue 9, p39 

    The article presents facts about Parkinson's disease (PD). Among the main symptoms of PD are abnormal shaking or tremor, slowness of movements and muscle stiffness or rigidity. Levodopa is the most important medicine for the treatment of PD. Regular exercise and physical therapy can help in...

  • Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system. Krystkowiak, Pierre; Blatt, Jean Louis; Bourriez, Jean Louis; Duhamel, Alain; Perina, Myriam; Kemoun, Gilles; Blond, Serge; Guieu, Jean Daniel; Dest�e, Alain; Defebvre, Luc // Journal of Neurology;Nov2001, Vol. 248 Issue 11, p944 

    Chronic bilateral internal globus pallidus (GPi) stimulation allows control of levodopa induced dyskinesias (LID) and motor symptoms in severe Parkinson's disease (PD). The effect on gait has not been clearly established. Different results have been reported, mostly consisting of clinical data....

  • Management of punding in Parkinson's disease: an open-label prospective study. Fasano, A.; Ricciardi, L.; Pettorruso, M.; Bentivoglio, A. R. // Journal of Neurology;Apr2011, Vol. 258 Issue 4, p656 

    Punding, a peculiar stereotyped behavior characterized by intense fascination with complex, excessive, non-goal-oriented, repetitive activities, is a quite rare condition complicating Parkinson's disease (PD). It is triggered by dopaminergic therapy and could have a strong impact on patient...

  • An update on the management of young-onset Parkinson's disease. Klepac, Nataša; Habek, Mario; Adamec, Ivan; Barušic, Anabella Karla; Bach, Ivo; Margetic, Eduard; Lušic, Ivo // Degenerative Neurological & Neuromuscular Disease;2013, Vol. 3, p53 

    In the text that follows, we review the main clinical features, genetic characteristics, and treatment options for Parkinson's disease (PD), considering the age at onset. The clinical variability between patients with PD points at the existence of subtypes of the disease. Identification of...

  • Pramipexole + Levodopa in Parkinson's Disease: Is the Whole Greater than the Sum of its Parts? Nirenberg, Melissa J. // Neurology Alert;Mar2010, Vol. 28 Issue 7, p52 

    LEVODOPA AND DOPAMINE AGONISTS (DAS) ARE commonly used treatments for Parkinson's disease (PD). Although DAs tend to have more side effects than levodopa, they are often favored as initial therapy because this strategy delays the onset of motor complications such as wearing off and dyskinesias....


Read the Article


Sign out of this library

Other Topics